2 Things Every Centrus Energy Investor Needs to Know

Centrus Energy, one of the only U.S.-owned uranium enrichers and the first licensed HALEU producer, has delivered 900 kg of HALEU under a DOE demonstration and earned an extension for another 900 kg in 2026, underpinning its strategic role in U.S. nuclear fuel supply. The company is profitable but lumpy: Q3 2025 net income was roughly $4 million on about $75 million of revenue versus Q2 net income of ~$29 million on ~$155 million; Centrus raised ~$805 million via convertible notes in August and finished Q3 with about $1.6 billion of unrestricted cash, though note conversion could dilute shareholders. The stock has surged over 218% year-to-date, but management warns revenues and earnings will remain uneven due to contract timing and pricing.

Analysis

Market structure: Centrus (LEU) is a de facto U.S. bottleneck for HALEU with a near-term captive buyer (DOE) — winners are LEU, U.S. utilities seeking HALEU, and domestic supply-chain contractors; losers include foreign enrichers that rely on Russian feed and miners that don’t convert to HALEU. The 900 kg delivery milestone and a DOE option for another 900 kg in 2026 create asymmetric pricing power for HALEU but translate into lumpy revenue (Q3: $75M rev/$4M NI vs Q2: $155M/$29M). This uniqueness supports a structural premium but only if advanced-reactor deployments materialize on multi-year timelines.

Risk assessment: Key tail risks are DOE funding withdrawal or policy reversal, operational failure at Piketon, or rapid, dilutive conversion of the $805M convertible that pressures the stock; net cash $1.6B cushions near-term capital needs but not program risk. Immediate (days) outcomes center on headlines and filings; short-term (weeks–months) on DOE milestone confirmations and quarterly volatility; long-term (years) on reactor build cadence and commercial off-takes. Hidden dependency: Centrus’ economics hinge on government-backed offtake and timing of SMR/advanced-reactor procurements rather than spot uranium prices.

Trade implications: Tactical bias is constructive but selective — LEU deserves a long-biased position sized to patient capital with downside protection. Catalysts to trade around: DOE contract extensions, quarterly delivery announcements, and any utility commercial HALEU contracts; expect 30–60% intra-year swings and plan sizing accordingly. Cross-asset: stronger HALEU fundamentals would be modestly bullish for uranium spot (U3O8) and increase implied equity vol, weigh against potential equity dilution risk.

Key Decisions for Investors

• Establish a 2–3% long position in Centrus Energy (LEU) equity within 30 days to capture the 2026 DOE HALEU delivery optionality; scale to full size only after another confirmed DOE contract extension or a commercial offtake announcement.
• Implement a pair trade: long LEU (2%) vs short Cameco (CCJ) (1–1.5%) to express HALEU-specific upside while hedging general uranium price risk; trim if LEU outperforms CCJ by >25% or if DOE cancels/defers deliveries.
• Buy 9–15 month LEU call options (or LEAPs) sized ~1% notional to lever upside to 2026 milestones, financed by selling near-term (30–90 day) calls or by implementing a collar; if buying stock, purchase a protective put ~30% OTM expiring 9–12 months to cap downside.
• Risk-control triggers: reduce LEU exposure by 50% if unrestricted cash falls below $1.0B, if share count rises >8% quarter-over-quarter (convertible conversion), or if DOE fails to exercise 2026 option within 90 days of delivery schedule — monitor SEC filings and DOE announcements daily for the next 90 days.